(VIANEWS) – Capital Southwest Corporation (CSWC), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Capital Southwest Corporation (CSWC)
41.3% sales growth and 11.92% return on equity
Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing. In lower middle market, the firm typically invests in growth financing, bolt-on acquisitions, new platform acquisitions, refinancing, dividend recapitalizations, sponsor-led buyouts, and management buyouts situations. The investment structures are Unitranche debt, subordinated debt, senior debt, first and second lien debt, and preferred and common equity. The firm makes equity co-investments alongside debt investments, up to 20% of total check and only makes non-control investments. It prefers to invest in Industrial manufacturing and services, value-added distribution, healthcare products and services, business services, specialty chemicals, food and beverage, tech-enabled services and SaaS models. The firm seeks to invest in energy services and products, industrial technologies, and specialty chemicals and products. Within energy services and products, the firm seeks to invest in each segment of the industry, including upstream, midstream and downstream, excluding exploration and production with a focus on differentiated products and services, equipment and tool rental, consumable products, and drilling and completion chemicals. Within industrial technologies, it seeks to invest in automation and process controls, handling and packaging equipment, industrial filtration and fluid handling, measurement, monitoring and testing, professional tools, and sensors and instrumentation. Within and specialty chemicals and products, the firm seeks to invest in businesses that develop and manufacture highly differentiated chemicals and products including adhesives, coatings and sealants, catalysts and absorbents, cosmeceuticals, fine chemicals, flavors and fragrances, performance lubricants, polymers, plastics and composites, chemical dispensing and filtration equipment, professional and industrial trade consumables and tools, engineered solutions for HVAC, plumbing, and electrical installations, specified high performance materials for fire protection and oilfield applications. It may also invest in exceptional opportunities in building products. The firm seeks to invest in the United States. The firm seeks to make investments ranging from $5 to $25 million in securities. It seeks to make equity investments up to $5 million and debt investments between $5 million and $20 million and co-invest in transaction size upto $40 million. It prefers to invest in companies with revenues approaching above $10 million, profitable operations, historical growth rate of at least 15 percent per year. . Within the lower middle market, it seeks to invest in with less than $15 million in EBITDA and also opportunistically invests in the upper middle market, generally defined as companies with EBITDA in excess of $50 million. In addition to making direct investments, the firm allocates capital to syndicated first and second lien term loans in the upper middle market. Criteria for Upper Middle Market Syndicated 1st Lien is EBITDA Size more than $30 million, Closing Leverage greater than 4 times, investment hold size between $5 million and $7 million, investment yield greater than 6.5%. Criteria for Upper Middle Market Syndicated 2nd Lien is EBITDA Size more than $50 million, Closing Leverage greater than 6 times, investment hold size between $5 million and $7 million, investment yield greater than 9%. It prefers to take a majority and minority stake. The firm has the flexibility to hold investments for very long period in its portfolio companies. It may also invest through warrants. The firm prefers to take Board participation in its portfolio companies. Capital Southwest Corporation was founded on April 19, 1961 and is based in Dallas, Texas.
Earnings Per Share
As for profitability, Capital Southwest Corporation has a trailing twelve months EPS of $1.85.
PE Ratio
Capital Southwest Corporation has a trailing twelve months price to earnings ratio of 12.36. Meaning, the purchaser of the share is investing $12.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.92%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 6.5% and 4.6%, respectively.
Sales Growth
Capital Southwest Corporation’s sales growth for the next quarter is 41.3%.
Previous days news about Capital Southwest Corporation(CSWC)
- According to Zacks on Thursday, 7 December, "Some better-ranked stocks in the broader Finance space are Cboe Global Markets, Inc. (CBOE Quick QuoteCBOE – Free Report) , Coinbase Global, Inc. (COIN Quick QuoteCOIN – Free Report) and Capital Southwest Corporation (CSWC Quick QuoteCSWC – Free Report) . "
2. Catalyst Pharmaceuticals (CPRX)
19.3% sales growth and 20.06% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 25.68. Meaning, the purchaser of the share is investing $25.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $14.12 at 19:22 EST, way under its 52-week high of $22.11 and way higher than its 52-week low of $11.09.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 239873 which is 80.14% below its average volume of 1207980.
Revenue Growth
Year-on-year quarterly revenue growth grew by 79.4%, now sitting on 348.39M for the twelve trailing months.
3. Exelixis (EXEL)
18.4% sales growth and 3.8% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.29.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 75.83. Meaning, the purchaser of the share is investing $75.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 355.6% and 58.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.6%, now sitting on 1.77B for the twelve trailing months.
Moving Average
Exelixis’s worth is higher than its 50-day moving average of $21.26 and above its 200-day moving average of $20.05.
Previous days news about Exelixis(EXEL)
- Exelixis (exel) collaborates with arcus for kidney cancer study. According to Zacks on Tuesday, 5 December, "Concurrently, Exelixis initiated a phase II/III STELLAR-305 study evaluating zanzalintinib in combination with Merck’s (MRK Quick QuoteMRK – Free Report) Keytruda (pembrolizumab) compared with standalone Keytruda in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck ("SCCHN")."
- According to Zacks on Thursday, 7 December, "Concurrently, Exelixis initiated a phase II/III STELLAR-305 study evaluating zanzalintinib in combination with Keytruda (pembrolizumab) compared with standalone Keytruda in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck ("SCCHN"). ", "Exelixis Collaborates With Arcus: Exelixis entered into a clinical collaboration with clinical-stage company Arcus Biosciences (RCUS Quick QuoteRCUS – Free Report) for its phase Ib/II study STELLAR-009. "
4. Dycom Industries (DY)
16% sales growth and 23.04% return on equity
Dycom Industries, Inc. provides specialty contracting services in the United States. The company offers various specialty contracting services, including program management, engineering, construction, maintenance, and installation services, such as placement and splicing of fiber, copper, and coaxial cables to telecommunications providers. It also provides tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; and installs and maintains customer premise equipment, such as digital video recorders, set top boxes, and modems for cable system operators. In addition, the company offers construction and maintenance services for electric and gas utilities, and other customers; and underground facility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines for various utility companies, including telecommunication providers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.
Earnings Per Share
As for profitability, Dycom Industries has a trailing twelve months EPS of $7.41.
PE Ratio
Dycom Industries has a trailing twelve months price to earnings ratio of 14.32. Meaning, the purchaser of the share is investing $14.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.04%.
Moving Average
Dycom Industries’s worth is way higher than its 50-day moving average of $87.73 and way higher than its 200-day moving average of $95.77.
Yearly Top and Bottom Value
Dycom Industries’s stock is valued at $106.12 at 19:22 EST, under its 52-week high of $115.53 and way above its 52-week low of $77.33.
Sales Growth
Dycom Industries’s sales growth is 5.4% for the present quarter and 16% for the next.
5. Sotherly Hotels (SOHO)
14.4% sales growth and 20.21% return on equity
Sotherly Hotels Inc. is a self-managed and self-administered lodging REIT focused on the acquisition, renovation, upbranding and repositioning of upscale to upper-upscale full-service hotels in the Southern United States. Currently, the Company's portfolio consists of investments in twelve hotel properties, comprising 3,156 rooms, as well as interests in two condominium hotels and their associated rental programs. The Company owns hotels that operate under the Hilton Worldwide, Hyatt Hotels Corporation, and Marriott International, Inc. brands, as well as independent hotels. Sotherly Hotels Inc. was organized in 2004 and is headquartered in Williamsburg, Virginia.
Earnings Per Share
As for profitability, Sotherly Hotels has a trailing twelve months EPS of $0.08.
PE Ratio
Sotherly Hotels has a trailing twelve months price to earnings ratio of 19.38. Meaning, the purchaser of the share is investing $19.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.21%.
Volume
Today’s last reported volume for Sotherly Hotels is 34818 which is 40.42% below its average volume of 58448.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Sotherly Hotels’s EBITDA is 1.91.
6. Boston Scientific (BSX)
8% sales growth and 6.68% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.82.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 66.74. Meaning, the purchaser of the share is investing $66.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Boston Scientific’s EBITDA is 6.59.
Yearly Top and Bottom Value
Boston Scientific’s stock is valued at $54.72 at 19:22 EST, below its 52-week high of $56.22 and way higher than its 52-week low of $44.35.
Previous days news about Boston Scientific(BSX)
- Boston Scientific (bsx) gains from global expansion, FX woe ails. According to Zacks on Tuesday, 5 December, "Within the Asia Pacific ("APAC"), Boston Scientific is particularly registering strong growth in Japan and China. ", "Additionally, following the pandemic-led mayhem, Boston Scientific is consistently registering fast recovery within its MedSurg segment. "
7. Fluor Corporation (FLR)
7.7% sales growth and 4.41% return on equity
Fluor Corporation provides engineering, procurement, and construction (EPC); fabrication and modularization; operation and maintenance; asset integrity; and project management services worldwide. It operates through four segments: Energy Solutions, Urban Solutions, Mission Solutions, and Other. The Energy Solutions provides solutions to the energy transition markets, including asset decarbonization, carbon capture, renewable fuels, waste-to-energy, green chemicals, hydrogen, nuclear power, and other low-carbon energy sources. It also provides consulting services, including feasibility studies, process assessments, and project finance structuring; and a range of services for small modular reactor technologies, as well as operation support services for nuclear power facilities and managing waste. This segment serves the oil, gas, and petrochemical industries. The Urban Solutions segment offers EPC and project management services to the infrastructure, advanced technologies, life sciences, and mining and metals industries. This segment also provides staffing services to the company and third-party clients with technical, professional, and craft resources on a contract or permanent placement basis. The Mission Solutions offers technical solutions to the U.S. and other governments. It also delivers solutions for nuclear security and operation, nuclear waste management, and laboratory management; and operation and maintenance, logistics, EPC, and life support solutions for mission-critical facilities across U.S. military service organizations. This segment offers site management, environmental remediation, and decommissioning for nuclear remediation at governmental facilities, as well as services to commercial nuclear clients. The Other segment researches, develops, licenses, and commercializes small modular nuclear reactor technology. It also provides unionized management and construction services. The company was founded in 1912 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Fluor Corporation has a trailing twelve months EPS of $0.71.
PE Ratio
Fluor Corporation has a trailing twelve months price to earnings ratio of 54.93. Meaning, the purchaser of the share is investing $54.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.41%.
Volume
Today’s last reported volume for Fluor Corporation is 1724920 which is 13.86% below its average volume of 2002610.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Fluor Corporation’s EBITDA is 0.36.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.7%, now sitting on 15.36B for the twelve trailing months.
Sales Growth
Fluor Corporation’s sales growth is 10.7% for the current quarter and 7.7% for the next.
Previous days news about Fluor Corporation(FLR)
- According to Zacks on Tuesday, 5 December, "Encashing Dow’s push for lower greenhouse gas emissions, Fluor Corporation (FLR Quick QuoteFLR – Free Report) won two contracts to construct the world’s first net-zero scope 1 and 2 emissions ethylene complex in Fort Saskatchewan, Alberta, Canada."
8. Ducommun Incorporated (DCO)
7.3% sales growth and 3.3% return on equity
Ducommun Incorporated provides engineering and manufacturing products and services primarily to the aerospace and defense, industrial, medical, and other industries in the United States. It operates through two segments, Electronic Systems and Structural Systems. The Electronic Systems segment provides cable assemblies and interconnect systems; printed circuit board assemblies; higher-level electronic, electromechanical, and mechanical components and assemblies, as well as lightning diversion systems; and radar enclosures, aircraft avionics racks, shipboard communications and control enclosures, shipboard communications and control enclosures, wire harnesses, surge suppressors, conformal shields, and other assemblies. It also supplies engineered products, including illuminated pushbutton switches and panels for aviation and test systems; microwave and millimeter switches and filters for radio frequency systems and test instrumentation; and motors and resolvers for motion control. In addition, this segment provides engineering expertise for aerospace system design, development, integration, and testing. The Structural Systems segment designs, engineers, and manufactures contoured aluminum, titanium, and Inconel aero structure components; structural assembly products, such as winglets, engine components, and fuselage structural panels; and metal and composite bonded structures and assemblies comprising aircraft wing spoilers, large fuselage skins, rotor blades on rotary-wing aircraft and components, flight control surfaces, engine components, and ammunition handling systems. It serves commercial aircraft, military fixed-wing aircraft, military and commercial rotary-wing aircraft, and space programs, as well as industrial, medical, and other end-use markets. The company was founded in 1849 and is headquartered in Santa Ana, California.
Earnings Per Share
As for profitability, Ducommun Incorporated has a trailing twelve months EPS of $1.44.
PE Ratio
Ducommun Incorporated has a trailing twelve months price to earnings ratio of 35.3. Meaning, the purchaser of the share is investing $35.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.3%.
Moving Average
Ducommun Incorporated’s worth is above its 50-day moving average of $46.88 and above its 200-day moving average of $47.75.
